The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...